Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.
最新数据
US$2.636
−US$0.054 · -2.01%
盘中时间采用ET。市场数据可能有所延迟。
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.
盘中时间采用ET。市场数据可能有所延迟。
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目(USD) | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 1.29亿 USD | 9959.7万 USD | 8357万 USD | 7205万 USD | 6744.9万 USD |
| 销货成本 | 4623.4万 USD | 3801.1万 USD | 3279万 USD | 2925.3万 USD | 2595.9万 USD |
| 毛利 | 8318.9万 USD | 6158.6万 USD | 5078万 USD | 4279.7万 USD | 4149万 USD |
| 研究与开发 | 633万 USD | 601.6万 USD | 495.8万 USD | 482.6万 USD | 383.2万 USD |
| 销售、一般及管理费用 | 6256.3万 USD | 4784.4万 USD | 5142.1万 USD | 5659.9万 USD | 6473.1万 USD |
| 营业费用 | 6889.3万 USD | 5386万 USD | 5637.9万 USD | 6142.5万 USD | 6856.3万 USD |
| 利息收入 | 212.7万 USD | 112.9万 USD | 66.1万 USD | 3000 USD | — |
| 利息支出 | — | — | — | — | 5.5万 USD |
| 折旧和摊销 | 145万 USD | 148.4万 USD | 170.5万 USD | 188.4万 USD | 162.6万 USD |
| 营业利润 | 1429.6万 USD | 772.6万 USD | −559.9万 USD | −1862.8万 USD | −2707.3万 USD |
| 净利润 | 1738.2万 USD | 855万 USD | −493.8万 USD | −1654万 USD | −2712.8万 USD |
公司数据更新于 2026年10月12日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2016年4月13日 | 1:3 | — | — |
已生效 2016年4月13日
1:3
报告持有此股票敞口的交易所交易基金。
Gabelli Love Our Planet & People ETFLOPP592.41万0.40%1470万 USD0.90%US$35.815-0.08%
Vanguard Morningstar Total Stock Market ETFVTI460.37万0.00%2.3万亿 USD0.03%US$381.2-0.19%
iShares Russell 2000 ETFIWM406.26万0.01%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF206.03万0.00%954亿 USD0.05%US$233.51-0.64%
Vanguard Consumer Staples ETFVDC186.16万0.02%93亿 USD0.09%US$228.68+1.02%
iShares Russell 2000 Growth ETFIWO145.64万0.01%139.17亿 USD0.24%US$353.68-0.87%
Vanguard Russell 2000 ETFVTWO103.77万0.01%180亿 USD0.06%US$112.26-0.36%
Schwab U.S. Small-Cap ETFSCHA80.66万0.00%218.24亿 USD0.03%US$32.665-0.38%
Gabelli Love Our Planet & People ETFLOPP
Vanguard Morningstar Total Stock Market ETFVTI
iShares Russell 2000 ETFIWM
Vanguard Extended Market ETFVXF
Vanguard Consumer Staples ETFVDC
iShares Russell 2000 Growth ETFIWO
Vanguard Russell 2000 ETFVTWO
Schwab U.S. Small-Cap ETFSCHAAI 生成内容及延迟市场数据仅供信息与教育用途,不构成投资建议。